Novo Nordisk stock price forecast: $42.19 support as NVO trades flat

Traders Union
All News
Financial News
Novo Nordisk slides 0.75% to $43.21

Highlights

UK approval of Novo Nordisk's oral Wegovy expands product access, strengthening the company's position in the obesity treatment market.
Novo Nordisk's majority owner is funding a €60 million pan-European R&D initiative targeting obesity and cardiometabolic innovation over six years.
NVO/USD trades under key moving averages, with technicals signaling sustained bearish momentum and a 75% probability of a move below $42.19.

Growth prospects expand as UK approval contrasts with share weakness

Novo Nordisk received UK regulatory approval for its oral Wegovy pill, immediately expanding the company's product lineup and access to the obesity treatment market, according to Simplywall. This regulatory milestone is likely to support future revenue streams by increasing patient reach and market share. Separately, the company's majority owner has initiated a pan-European research program focused on obesity and cardiometabolic diseases, with DKK 450 million committed over six years to early-stage innovation, as reported by Finance Yahoo. These developments have occurred as price action has remained under broader selling pressure.

Bearish bias as price lags moving averages and signals diverge

NVO is trading below the MA-20 at $43.62 and MA-50 at $43.7 on the H1 chart, with significant separation from the long-term MA-200 at $48.15 on the daily timeframe. The Kijun line from the Ichimoku indicator is positioned at $43.76, marking a key resistance to the upside. Support is defined by the lower band at $42.19, with resistance near $44.23. Among momentum indicators, MACD signals Sell, ADX is Neutral, and Bull/Bear Power shows seller dominance. The RSI stands at 43.34 (Sell), CCI is in Sell territory, while Stoch RSI registers a Strong Buy, and the Awesome Oscillator remains Neutral, reflecting conflicting signals across oscillators and momentum measures.

Consolidation likely as downside risk outweighs bullish breakout

In the short term, NVO is expected to consolidate within the $42.19 to $44.23 range, representing the current volatility band relative to recent levels. The probability of a downside move is estimated at 75%, compared to a 25% chance for an upward bounce. Should price rise above $43.76, a bullish breakout scenario could unfold; however, a drop below $42.19 would likely trigger additional selling momentum.

Anton Kharitonov, analyst at Traders Union, notes Novo Nordisk’s recent regulatory and research milestones but stresses ongoing market weakness. He sees technical signals and moving averages still pressuring the stock despite constructive fundamental news. The analyst maintains a cautious view until resistance levels are reclaimed. "Until $43.76 is decisively broken, the bias is to the downside and any long trades remain high risk."

Previously it was reported that analysts remained cautious on Novo Nordisk due to persistent downside momentum and operational uncertainties. The addition of UK approval for the oral Wegovy pill and increased research investment adds fresh tailwinds to the long-term story, but with technical resistance and selling pressure still dominant, investors should focus on $43.76 as the pivotal level for any sustained bullish reversal.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.